Drug news
NICE rejects Xalkori (Pfizer) for treatment of Non Small Cell Lung Cancer
The National Institute for Health and Clinical Excellence (NICE) has issued new draft guidance in which it does not recommend Xalkori (crizotinib),the tyrosine kinase inhibitor from Pfizer. for use in previously treated anaplastic-lymphoma-kinase-(ALK) positive advanced Non-Small-Cell Lung Cancer (NSCLC), but has opened a public consultation on this preliminary decision. NICE did not view the drug as being cost effective.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.